Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).
Purity:
99.0%
CAS Number:
[916138-87-9]
* VAT and and shipping costs not included. Errors and price changes excepted